TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Results of Operations and Financial Condition

TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Results of Operations and Financial Condition
Story continues below

On August 13, 2018, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended June 30, 2018. A copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report.

Item7.01 Regulation FD Disclosure.

The Company updated its investor presentations, which are used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. Copies of the presentations are filed as Exhibit 99.02 and 99.03 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.


Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.1 2 s112012_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights HONOR Study Results to be Included in Poster Presentation at a Scientific Conference in August 2018 FDA Meeting in October 2018 Confirmed to Discuss New Phase 3 Study for Tonmya® in PTSD New Phase 3 Study for Tonmya May Initiate as Early as 2019 NEW YORK,…
To view the full exhibit click here

An ad to help with our costs